Educational Advancements Made in Treatment of Merkel Cell Carcinoma
Lyn Brook
Practice Patterns
i3 Health has provided a continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma, that enabled the health care team to acquire significant gains in proficiency and knowledge for treating their patients with Merkel cell carcinoma ...
Cemiplimab for Metastatic Basal Cell Carcinoma: Exploring the Data With Karl Lewis, MD
Keira Smith
Expert Analysis
Cemiplimab, a programmed cell death protein 1 (PD-1) inhibitor, was approved in 2021 as the first and only systemic therapy to demonstrate clinical benefit among patients with advanced basal cell carcinoma (BCC) previously treated with hedgehog pathway inhibitor (HHI) therapy. At the American Association for Cancer Research (AACR) Annual Meeting in...
Navigating the Selection of Immunotherapy in Metastatic Melanoma With Benjamin Izar, MD
Lyn Brook
Expert Analysis
Recently, the FDA approved the combination of relatlimab plus nivolumab for patients with unresectable or metastatic melanoma. However, many challenges remain in the selection of patients who will benefit from these agents and in determining alternative options for those who are ineligible for the combination. In this interview in honor of Melanoma...
Combination of Nivolumab and Relatlimab Approved for Unresectable or Metastatic Melanoma
Lyn Brook
FDA Updates
The FDA has approved the combination of nivolumab and relatlimab-rmbw (Opdualag™, Bristol-Myers Squibb) for patients with unresectable or metastatic melanoma. OpdualagTM is a fixed-dose dual immunotherapy combination of nivolumab, a programmed cell death protein 1 (PD-1)–blocking antibody, and relatlimab, a first-in-class human lymphocyte–activatio...

Copyright © Oncology Data Advisor. All rights reserved.